Charles River Laboratories International (NYSE:CRL) Price Target Lowered to $184.00 at Morgan Stanley

Charles River Laboratories International (NYSE:CRL) had its target price decreased by Morgan Stanley from $220.00 to $184.00 in a research note issued to investors on Wednesday,Benzinga reports. Morgan Stanley currently has an equal weight rating on the medical research company’s stock.

CRL has been the topic of several other reports. JPMorgan Chase & Co. dropped their price target on shares of Charles River Laboratories International from $215.00 to $175.00 and set a “neutral” rating on the stock in a research report on Monday. CLSA cut Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 target price on the stock. in a report on Monday, November 18th. The Goldman Sachs Group reduced their price objective on shares of Charles River Laboratories International from $220.00 to $190.00 and set a “buy” rating for the company in a research note on Thursday, January 23rd. Evercore ISI lifted their target price on shares of Charles River Laboratories International from $190.00 to $225.00 and gave the company an “in-line” rating in a research note on Thursday, November 7th. Finally, UBS Group reaffirmed a “neutral” rating and set a $185.00 target price (down previously from $250.00) on shares of Charles River Laboratories International in a research report on Friday, January 17th. Three research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and one has issued a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $200.79.

Charles River Laboratories International Stock Performance

CRL stock opened at $165.70 on Wednesday. The company has a 50-day simple moving average of $181.99 and a 200 day simple moving average of $194.26. The company has a market capitalization of $8.47 billion, a P/E ratio of 20.74, a PEG ratio of 6.25 and a beta of 1.37. The company has a quick ratio of 1.14, a current ratio of 1.48 and a debt-to-equity ratio of 0.61. Charles River Laboratories International has a fifty-two week low of $159.65 and a fifty-two week high of $275.00.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings results on Wednesday, November 6th. The medical research company reported $2.59 earnings per share for the quarter, topping analysts’ consensus estimates of $2.43 by $0.16. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. The company had revenue of $1.01 billion during the quarter, compared to analyst estimates of $975.99 million. During the same period in the prior year, the business posted $2.72 EPS. The business’s revenue for the quarter was down 1.6% compared to the same quarter last year. Sell-side analysts predict that Charles River Laboratories International will post 10.17 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. SRS Capital Advisors Inc. grew its holdings in Charles River Laboratories International by 115.5% in the fourth quarter. SRS Capital Advisors Inc. now owns 390 shares of the medical research company’s stock worth $72,000 after purchasing an additional 209 shares during the period. Smartleaf Asset Management LLC increased its position in shares of Charles River Laboratories International by 61.6% during the 4th quarter. Smartleaf Asset Management LLC now owns 459 shares of the medical research company’s stock valued at $84,000 after purchasing an additional 175 shares during the last quarter. Metis Global Partners LLC raised its position in Charles River Laboratories International by 4.4% in the fourth quarter. Metis Global Partners LLC now owns 1,720 shares of the medical research company’s stock worth $318,000 after acquiring an additional 72 shares during the period. Fisher Asset Management LLC raised its holdings in shares of Charles River Laboratories International by 25.8% in the 4th quarter. Fisher Asset Management LLC now owns 232,318 shares of the medical research company’s stock worth $42,886,000 after purchasing an additional 47,626 shares during the period. Finally, QRG Capital Management Inc. purchased a new position in shares of Charles River Laboratories International during the 4th quarter valued at $255,000. Institutional investors and hedge funds own 98.91% of the company’s stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).